{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:07:05Z","timestamp":1785272825914,"version":"3.55.0"},"reference-count":91,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2026,2,28]]},"DOI":"10.5582\/bst.2025.01271","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T22:07:37Z","timestamp":1763503657000},"page":"45-47","source":"Crossref","is-referenced-by-count":1,"title":["Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates"],"prefix":"10.5582","volume":"20","author":[{"given":"Xinyue","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Draggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weishuai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pain Management, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antao","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Draggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihui","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Draggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020; 395:2008-2020.","DOI":"10.1016\/S0140-6736(20)30974-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Dimastromatteo J, He J, Adams RB, Kelly KA. Imaging cell surface plectin in PDAC patients - A first-in-human phase 0 study report. Mol Imaging Biol. 2025; 27:389-399.","DOI":"10.1007\/s11307-025-02001-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY, Gao F. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021; 27:4298-4321.","DOI":"10.3748\/wjg.v27.i27.4298"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Martinez-Bosch N, Vinaixa J, Navarro P. Immune evasion in pancreatic cancer: From mechanisms to therapy. Cancers. 2018; 10:6.","DOI":"10.3390\/cancers10010006"},{"key":"5","unstructured":"5. Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017; 32:185-203.e13."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol. 2023; 18:123-148.","DOI":"10.1146\/annurev-pathmechdis-031621-024600"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tirpe A, Streianu C, Isachesku E, Simon I, Berindan-Neagoe I. The road to overcome pancreatic cancer: Where are we? Heliyon. 2024; 10:e38196.","DOI":"10.1016\/j.heliyon.2024.e38196"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Zhen DB, Safyan RA, Konick EQ, Nguyen R, Prichard CC, Chiorean EG. The role of molecular testing in pancreatic cancer. Ther Adv Gastroenterol. 2023; 16:17562848231171456.","DOI":"10.1177\/17562848231171456"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nagaraju GP, Farran B, Luong T, El-Rayes BF. Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistance: A brief overview. Semin Cancer Biol. 2023; 88:67-80.","DOI":"10.1016\/j.semcancer.2022.12.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M, Weidner P, Leipertz A, Teufel A, Ebert MP. Digestive cancers: Mechanisms, therapeutics and management. Signal Transduct Target Ther. 2025; 10:24.","DOI":"10.1038\/s41392-024-02097-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Theocharopoulos C, Ziogas IA, Douligeris CC, Efstathiou A, Kolorizos E, Ziogas DC, Kontis E. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: &quot;Magic bullets&quot; to the rescue? Cancer Treat Rev. 2024; 129:102806.","DOI":"10.1016\/j.ctrv.2024.102806"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers. 2023; 15:713.","DOI":"10.3390\/cancers15030713"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yajaman DR, Oh Y, Trevino JG, Harrell JC. Advancing antibody-drug conjugates: Precision oncology approaches for breast and pancreatic cancers. Cancers. 2025; 17:1792.","DOI":"10.3390\/cancers17111792"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: Fact or fiction? Curr Oncol Rep. 2022; 24:809-817.","DOI":"10.1007\/s11912-022-01266-4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tang H, Liu Y, Yu Z, Sun M, Lin L, Liu W, Han Q, Wei M, Jin Y. The analysis of key factors related to ADCs structural design. Front Pharmacol. 2019; 10:373.","DOI":"10.3389\/fphar.2019.00373"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Xing L, Lv L, Ren J, Yu H, Zhao X, Kong X, Xiang H, Tao X, Dong D. Advances in targeted therapy for pancreatic cancer. Biomed Pharmacother. 2023; 168:115717.","DOI":"10.1016\/j.biopha.2023.115717"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: The &quot;biological missile&quot; for targeted cancer therapy. Signal Transduct Target Ther. 2022; 7:93.","DOI":"10.1038\/s41392-022-00947-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wittwer NL, Brown MP, Liapis V, Staudacher AH. Antibody drug conjugates: Hitting the mark in pancreatic cancer? J Exp Clin Cancer Res. 2023; 42:280.","DOI":"10.1186\/s13046-023-02868-x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Metrangolo V, Ploug M, Engelholm LH. The urokinase receptor (uPAR) as a &quot;Trojan horse&quot; in targeted cancer therapy: Challenges and opportunities. Cancers (Basel). 2021; 13:5376.","DOI":"10.3390\/cancers13215376"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Peng L, Li Y, Yao S, Gaedcke J, Baart VM, Sier CFM, Neesse A, Ellenrieder V, Bohnenberger H, Fuchs F, Kitz J, Str\u00f6bel P, K\u00fcffer S. Urokinase-type plasminogen activator receptor (uPAR) cooperates with mutated KRAS in regulating cellular plasticity and gemcitabine response in pancreatic adenocarcinomas. Cancers. 2023; 15:1587.","DOI":"10.3390\/cancers15051587"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kumar AA, Buckley BJ, Ranson M. The urokinase plasminogen activation system in pancreatic cancer: Prospective diagnostic and therapeutic targets. Biomolecules. 2022; 12:152.","DOI":"10.3390\/biom12020152"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, Neesse A. Microenvironmental determinants of pancreatic cancer. Physiol Rev. 2020; 100:1707-1751.","DOI":"10.1152\/physrev.00042.2019"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Metrangolo V, Blomquist MH, Dutta A, G\u00e5rdsvoll H, Krigslund O, N\u00f8rregaard KS, J\u00fcrgensen HJ, Ploug M, Flick MJ, Behrendt N, Engelholm LH. Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models. Sci Adv. 2025; 11:eadq0513.","DOI":"10.1126\/sciadv.adq0513"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lv J, Li P. Mesothelin as a biomarker for targeted therapy. Biomark Res. 2019; 7:18.","DOI":"10.1186\/s40364-019-0169-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chu GJ, Linton A, Kao S, Klebe S, Adelstein S, Yeo D, Rasko JEJ, Cooper WA. High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma. Histopath. 2023; 83:202-210.","DOI":"10.1111\/his.14916"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Chu Q. Targeting Mesothelin in Solid Tumours: Anti-mesothelin antibody and drug conjugates. Curr Oncol Rep. 2023; 25:309-323.","DOI":"10.1007\/s11912-023-01367-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Wittwer N, Staudacher A, Liapis V, Cardarelli P, Warren H, Brown M. An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer. J Immunother Cancer. 2023; 11:e006274.","DOI":"10.1136\/jitc-2022-006274"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hassan R, Blumenschein GR, Moore KN, <i>et al.<\/i> First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J Clin Oncol. 2020; 38:1824-1835.","DOI":"10.1200\/JCO.19.02085"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Katoh M, Katoh M. Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review). Int J Mol Med. 2024; 54:100.","DOI":"10.3892\/ijmm.2024.5424"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Xu Q, Jia C, Ou Y, Zeng C, Jia Y. Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer. Front Oncol. 2024; 14:1371421.","DOI":"10.3389\/fonc.2024.1371421"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. O&apos;Brien NA, McDermott MSJ, Zhang J , <i>et al.<\/i> Development of a novel CLDN18.2-directed monoclonal antibody and antibody-drug conjugate for treatment of CLDN18.2-positive cancers. Mol Cancer Ther. 2023; 22:1365-1375.","DOI":"10.1158\/1535-7163.MCT-23-0353"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Lu Z, Shi M, Zheng X, Liang Y, Wang J, Zou Z, Luo R, Feng M, Yang X, Zhou Y, Li X. Preclinical evaluation of 89Zr\/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma. Int J Pharm. 2024; 667:124946.","DOI":"10.1016\/j.ijpharm.2024.124946"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ruan DY, Liu FR, Wei XL, <i>et al.<\/i> Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): A multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025; 26:227-238.","DOI":"10.1016\/S1470-2045(24)00636-3"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Xu G, Liu W, Wang Y, Wei X, Liu F, He Y, Zhang L, Song Q, Li Z, Wang C, Xu R, Chen B. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep Med. 2024; 5:101710.","DOI":"10.1016\/j.xcrm.2024.101710"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Zhou KI, Strickler JH, Chen H. Targeting Claudin-18.2 for cancer therapy: Updates from 2024 ASCO annual meeting. J Hematol Oncol. 2024; 17:73.","DOI":"10.1186\/s13045-024-01595-w"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Yu X, Zhang J, Tazbirkova A, <i>et al.<\/i> Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study. J Clin Oncol. 2024; 42:3037-3037.","DOI":"10.1200\/JCO.2024.42.16_suppl.3037"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Hao J, Zheng L, Ruihong D, <i>et al.<\/i> Safety and efficacy of IBI389, an anti-CLDN18.2\/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study. J Clin Oncol. 2024; 42:4011-4011.","DOI":"10.1200\/JCO.2024.42.16_suppl.4011"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Pratt EC, Mandleywala K, Bauer D, Bolaender A, Chao G, Castanares MA, Collins EC, Lewis JS. Pretargeted Trop-2 immunoPET for rapid, selective detection of pancreatic tumors. Clin Cancer Res. 2025; 31:2719-2726.","DOI":"10.1158\/1078-0432.CCR-24-3098"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Liu Y, Huang W, Saladin RJ, Hsu JC, Cai W, Kang L. Trop2-targeted molecular imaging in solid tumors: Current advances and future outlook. Mol Pharm. 2024; 21:5909-5928.","DOI":"10.1021\/acs.molpharmaceut.4c00848"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Sun LP, Bai WQ, Zhou DD, Wu XF, Zhang LW, Cui AL, Xie ZH, Gao RJ, Zhen YS, Li ZR, Miao QF. hIMB1636-MMAE, a novel TROP2-targeting antibody-drug conjugate exerting potent antitumor efficacy in pancreatic cancer. J Med Chem. 2023; 66:14700-14715.","DOI":"10.1021\/acs.jmedchem.3c01210"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Xu C, Huang X, Hu Q, Xue W, Zhou K, Li X, Nan Y, Ju D, Wang Z, Zhang X. Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer. Biomed Pharmacother. 2024; 180:117550.","DOI":"10.1016\/j.biopha.2024.117550"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Bardia A, Tolaney SM, Loirat D, <i>et al.<\/i> Sacituzumab govitecan (SG) versus treatment of physician&apos;s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. J Clin Oncol. 2022; 40:1071-1071.","DOI":"10.1200\/JCO.2022.40.16_suppl.1071"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Xu C, Zhu M, Wang Q, Cui J, Huang Y, Huang X, Huang J, Gai J, Li G, Qiao P, Zeng X, Ju D, Wan Y, Zhang X. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer. J Nanobiotech. 2023; 21:410.","DOI":"10.1186\/s12951-023-02183-9"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Oaknin A, Lee JY, Makker V, <i>et al.<\/i> Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: Post hoc analysis of DESTINY-PanTumor02. Adv Ther. 2024; 41:4125-4139.","DOI":"10.1007\/s12325-024-02975-x"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Gupta A, Michelini F, Shao H, <i>et al.<\/i> EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Rep Med. 2024; 5:101792.","DOI":"10.1016\/j.xcrm.2024.101792"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Yao H, Yan M, Tong Z, <i>et al.<\/i> Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2-directed antibody-drug conjugate, in human epidermal growth factor receptor 2-expressing or mutated advanced solid tumors: A global phase I trial. J Clin Oncol. 2024; 42:3453-3465.","DOI":"10.1200\/JCO.23.02044"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Jones L, Cunningham D, Starling N. HER-2 directed therapies across gastrointestinal tract cancers - A new frontier. Cancer Treat Rev. 2024; 129:102789.","DOI":"10.1016\/j.ctrv.2024.102789"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Meric-Bernstam F, Makker V, Oaknin A, <i>et al.<\/i> Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024; 42:47-58.","DOI":"10.1200\/JCO.23.02005"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Perovic D, Dusanovic Pjevic M, Perovic V, Grk M, Rasic M, Milickovic M, Mijovic T, Rasic P. B7 homolog 3 in pancreatic cancer. World J Gastroenterol. 2024; 30:3654-3667.","DOI":"10.3748\/wjg.v30.i31.3654"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Brignole C, Calarco E, Bensa V, Giusto E, Perri P, Ciampi E, Corrias MV, Astigiano S, Cilli M, Loo D, Bonvini E, Pastorino F, Ponzoni M. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. J Immunother Cancer. 2023; 11:e007174.","DOI":"10.1136\/jitc-2023-007174"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Zhu M, Zhou L, Hu S, Miao Q, Gong J, Zhang N, Zhang G, Wang M, Wang J, He H, Wang Y. Rational design and systemic appraisal of an EGFR-targeting antibody-drug conjugate LR-DM1 for pancreatic cancer. J Med Chem. 2022; 65:7141-7153.","DOI":"10.1021\/acs.jmedchem.1c01920"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Chang HW, Frey G, Wang J, Liu H, Xing C, Chen J, Boyle WJ, Short JM. Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate. MAbs. 2025; 17:2490078.","DOI":"10.1080\/19420862.2025.2490078"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Romero-P\u00e9rez I, Montero JC, Redondo-Puente M, Del Carmen G\u00f3mez-Garc\u00eda M, Morell-Ginest\u00e0 M, Capell\u00e1 G, Pandiella A. An antibody-drug conjugate targeting soluble and membrane-bound TGF\u03b1 is effective against pancreatic tumors. J Exp Clin Cancer Res. 2025; 44:158.","DOI":"10.1186\/s13046-025-03421-8"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Garrett JT, Tendler S, Feroz W, Kilroy MK, Yu H. Emerging importance of HER3 in tumorigenesis and cancer therapy. Nat Rev Clin Oncol. 2025; 22:348-370.","DOI":"10.1038\/s41571-025-01008-y"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Weng W, Meng T, Pu J, <i>et al.<\/i> AMT-562, a novel HER3-targeting antibody-drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors. Mol Cancer Ther. 2023; 22:1013-1027.","DOI":"10.1158\/1535-7163.MCT-23-0198"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Fu R, Wang C, Yin T, Zhang X, Xu Y, Shi Y, Xu J, Zhang W, Ding Z. A novel and promising therapeutic approach for treating pancreatic cancer: Nectin\u20114\u2011targeted antibody\u2011drug conjugates alone or combined with autophagy inhibitors. Int J Mol Med. 2025; 55:66.","DOI":"10.3892\/ijmm.2025.5507"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Zhang J, Liu R, Wang S, <i>et al.<\/i> Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: A first-in-human, open-label, multicenter, phase I\/II study. Ann Oncol. 2025; 36:934-943.","DOI":"10.1016\/j.annonc.2025.04.009"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Fukuokaya W, Koike Y, Yata Y, <i>et al.<\/i> Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study. Int J Urol. 2024; 31:342-347.","DOI":"10.1111\/iju.15368"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Zhu XY, Li QX, Kong Y, Huang KK, Wang G, Wang YJ, Lu J, Hua GQ, Wu YL, Ying TL. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent <i>in vitro<\/i> and <i>in vivo<\/i> antitumor activity. Acta Pharmacol Sin. 2024; 45:609-618.","DOI":"10.1038\/s41401-023-01200-9"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Kim YJ, Li W, Zhelev DV, Mellors JW, Dimitrov DS, Baek DS. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. Front Oncol. 2023; 13:1124039.","DOI":"10.3389\/fonc.2023.1124039"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Kogai H, Tsukamoto S, Koga M, Miyano M, Akagi T, Yamaguchi A, Mori K, Gotoh K, Nakazawa Y. Broad-spectrum efficacy of CEACAM6-targeted antibody-drug conjugate with BET protein degrader in colorectal, lung, and breast cancer mouse models. Mol Cancer Ther. 2025; 24:392-405.","DOI":"10.1158\/1535-7163.MCT-24-0444"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Kong Y, Xie F, Zhang Z, <i>et al.<\/i> Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma. Eur Radiol. 2023; 33:7077-7088.","DOI":"10.1007\/s00330-023-09679-w"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Cardenas KCA, Enos CW, Spear MR, Austin DE, Almofeez R, Kortchak S, Pincus L, Guo H-B, Dolezal S, Pierce JM, Furth E, Gineste C, Kwon Y, Gelber C. CT109-SN-38, a Novel antibody-drug conjugate with dual specificity for CEACAM5 and 6, elicits potent killing of pancreatic cancer cells. Curr Cancer Drug Targets. 2024; 24:720-732.","DOI":"10.2174\/0115680096260614231115192343"},{"key":"64","unstructured":"64. ecancer. ASCO 2025: Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study of antibody-drug conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology. (ASCO) <i>http:\/\/ecancer.org\/en\/news\/26567-asco-2025-experimental-drug-development-centre-announces-the-presentation-of-updated-data-from-the-phase-1-study-of-antibody-drug-conjugate-ebc-129-at-the-2025-annual-meeting-of-the-american-society-of-clinical-oncology-asco<\/i> (accessed August 1, 2025)."},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Chang FL, Lee CC, Tsai KC, Lin TY, Chiang CW, Pan SL, Lee YC. An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment. Biochem Biophys Res Commun. 2023; 688:149214.","DOI":"10.1016\/j.bbrc.2023.149214"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Lyon RP, Jonas M, Frantz C, Trueblood ES, Yumul R, Westendorf L, Hale CJ, Stilwell JL, Yeddula N, Snead KM, Kumar V, Patilea-Vrana GI, Klussman K, Ryan MC. SGN-B6A: A new vedotin antibody-drug conjugate directed to integrin beta-6 for multiple carcinoma indications. Mol Cancer Ther. 2023; 22:1444-1453.","DOI":"10.1158\/1535-7163.MCT-22-0817"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Zheng C, Zhou D, Li W, Duan Y, Xu M, Liu J, Cheng J, Xiao Y, Xiao H, Gan T, Liang J, Zheng D, Wang L, Zhang S. Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer. Cell Death Dis. 2023; 14:295.","DOI":"10.1038\/s41419-023-05820-1"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Mazahreh R, Mason ML, Gosink JJ, <i>et al.<\/i> SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models. Mol Cancer Ther. 2023; 22:421-434.","DOI":"10.1158\/1535-7163.MCT-22-0401"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Wu G, Li L, Liu M, Chen C, Wang G, Jiang Z, Qin Y, He L, Li H, Cao J, Gu H. Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. Cancer Cell Int. 2022; 22:417.","DOI":"10.1186\/s12935-022-02839-w"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Huang J, Agoston AT, Guo P, Moses MA. A rationally designed ICAM1 antibody drug conjugate for pancreatic cancer. Adv Sci (Weinh). 2020; 7:2002852.","DOI":"10.1002\/advs.202002852"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Mosley M, Bagu\u00f1a Torres J, Allen D, Cornelissen B. Immuno-imaging of ICAM-1 in tumours by SPECT. Nucl Med Biol. 2020; 84-85:73-79.","DOI":"10.1016\/j.nucmedbio.2020.02.014"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Chu X, Shin S, Baek DS, <i>et al.<\/i> Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer. MAbs. 2024; 16:2387240.","DOI":"10.1080\/19420862.2024.2387240"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Zhang Z, Tao J, Qiu J, Cao Z, Huang H, Xiao J, Zhang T. From basic research to clinical application: Targeting fibroblast activation protein for cancer diagnosis and treatment. Cell Oncol (Dordr). 2024; 47:361-381.","DOI":"10.1007\/s13402-023-00872-z"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Busato D, Mossenta M, Dal Bo M, Macor P, Toffoli G. The proteoglycan glypican-1 as a possible candidate for innovative targeted therapeutic strategies for pancreatic ductal adenocarcinoma. Int J Mol Sci. 2022; 23:10279.","DOI":"10.3390\/ijms231810279"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Wu Y, Li Q, Kong Y, <i>et al.<\/i> A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Mol Ther. 2022; 30:2785-2799.","DOI":"10.1016\/j.ymthe.2022.04.013"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Ma Y, Huang Y, Zhao Y, <i>et al.<\/i> BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024; 25:901-911.","DOI":"10.1016\/S1470-2045(24)00159-1"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Wang M, Ma Q, Suthe SR, Hudson RE, Pan JY, Mikelis C, Zhu MJ, Wu ZG, Shi DR, Yao HP. Humanized dual-targeting antibody-drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity. Acta Pharmacol Sin. 2025; 46:1375-1389.","DOI":"10.1038\/s41401-024-01458-7"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Goldmacher VS, Gershteyn I, Chari R, Kovtun Y. A bispecific anti-MUC16\/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated tumor regression. Sci Rep. 2025; 15:9909.","DOI":"10.1038\/s41598-025-93927-0"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, Chen S, Pan L. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022; 7:39.","DOI":"10.1038\/s41392-021-00868-x"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Dai H, Chen X, Yang J, Wang Y, Loiola RA, Lu A, Cheung KCP. Insights and therapeutic advances in pancreatic cancer: The role of electron microscopy in decoding the tumor microenvironment. Front Cell Dev Biol. 2024; 12:1460544.","DOI":"10.3389\/fcell.2024.1460544"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Xiao Y, Pan T, Da W, Liu Y, Chen S, Chen D, Liu K, Zheng Y, Xie D, Gao Y, Xu H, Sun Y, Tan W. Aptamer-drug conjugates-loaded bacteria for pancreatic cancer synergistic therapy. Signal Transduct Target Ther. 2024; 9:272.","DOI":"10.1038\/s41392-024-01973-3"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Li T, Yu X, Wan X, Liu J, Zheng J, Sun Z, Zhao Y, Chen J, Chen H, Yang Y, Jiang B. Exploiting synthetic lethality in PDAC with antibody drug conjugates and ATR inhibition. Eur J Med Chem. 2025; 286:117305.","DOI":"10.1016\/j.ejmech.2025.117305"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Tsujii S, Serada S, Fujimoto M, Uemura S, Namikawa T, Nomura T, Murakami I, Hanazaki K, Naka T. Glypican-1 is a novel target for stroma and tumor cell dual-targeting antibody-drug conjugates in pancreatic cancer. Mol Cancer Ther. 2021; 20:2495-2505.","DOI":"10.1158\/1535-7163.MCT-21-0335"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Munekage E, Serada S, Tsujii S, Yokota K, Kiuchi K, Tominaga K, Fujimoto M, Kanda M, Uemura S, Namikawa T, Nomura T, Murakami I, Hanazaki K, Naka T. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia. 2021; 23:939-950.","DOI":"10.1016\/j.neo.2021.07.006"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Tsumura R, Anzai T, Koga Y, Takashima H, Matsumura Y, Yasunaga M. Anti-tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models. Cancer Sci. 2024; 115:3986-3996.","DOI":"10.1111\/cas.16335"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Nieto-Jim\u00e9nez C, Sanvicente A, D\u00edaz-Tejeiro C, Moreno V, Lopez de S\u00e1 A, Calvo E, Mart\u00ednez-L\u00f3pez J, P\u00e9rez-Segura P, Oca\u00f1a A. Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates. Clin Transl Med. 2023; 13:e1329.","DOI":"10.1002\/ctm2.1329"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Li Q, Kong Y, Zhong Y, Huang A, Ying T, Wu Y. Half-life extension of single-domain antibody-drug conjugates by albumin binding moiety enhances antitumor efficacy. MedComm. 2024; 5:e557.","DOI":"10.1002\/mco2.557"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Wang H, Huangfu S, Wei D, Sun Z, Wu Y, Yu X, Jiang B, Chen H. Triptolide-based cleavable antibody-drug conjugates for pancreatic cancer. Eur J Med Chem. 2025; 295:117798.","DOI":"10.1016\/j.ejmech.2025.117798"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Papacharisi E, Braun AC, Vranic M, Pahl AM, Hechler T. Novel amanitin-based antibody-drug conjugates targeting TROP2 for the treatment of pancreatic cancer. Mol Cancer Ther. 2025; 24:485-496.","DOI":"10.1158\/1535-7163.MCT-24-0266"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Nakazawa Y, Miyano M, Tsukamoto S, <i>et al.<\/i> Delivery of a BET protein degrader <i>via<\/i> a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models. Nat Commun. 2024; 15:2192.","DOI":"10.1038\/s41467-024-46167-1"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Guo Y, Shen Z, Zhao W, <i>et al.<\/i> Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors. Adv Sci (Weinh). 2024; 11:e2306309.","DOI":"10.1002\/advs.202306309"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/1\/20_2025.01271\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:59:20Z","timestamp":1772859560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/1\/20_2025.01271\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2025.01271","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"article-number":"2025.01271"}}